Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Lindbrook Capital LLC

Lindbrook Capital LLC lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 82.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 389 shares of the specialty pharmaceutical company’s stock after acquiring an additional 176 shares during the period. Lindbrook Capital LLC’s holdings in Jazz Pharmaceuticals were worth $48,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in JAZZ. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after acquiring an additional 100,112 shares during the last quarter. GW&K Investment Management LLC lifted its position in Jazz Pharmaceuticals by 26.6% during the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after buying an additional 97,589 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $11,373,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Buy” and an average price target of $189.40.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $138.81 on Friday. The stock’s 50-day moving average is $128.14 and its 200-day moving average is $120.03. The company has a market cap of $8.43 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,193 shares of company stock worth $3,533,122 in the last three months. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.